

July 20, 2021

To,
SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

Dear Sirs/Madam,

Sub: Filing and approval of the Red Herring Prospectus ("RHP") dated July 19, 2021 of our wholly owned subsidiary "Glenmark Life Sciences Limited" in connection with its proposed initial public offering of equity shares ("Offer" or "IPO")

Further to our intimation dated April 16, 2021 regarding submission of the draft red herring prospectus dated April 16, 2021 ("DRHP") with the Securities and Exchange Board of India, by our wholly owned subsidiary, Glenmark Life Sciences Limited, please be informed that on July 19, 2021, Glenmark Life Sciences Limited had filed the RHP with the Registrar of Companies, Pune at Maharashtra ("ROC") in connection with the Offer. The RHP has been taken on record by the ROC on July 20, 2021.

The details and timelines for the proposed Offer are as under:

Fresh Issue	Up to ₹10,600 million
Offer for Sale by Glenmark Pharmaceuticals Limited	Up to 6,300,000 Equity Shares
Anchor investor Bid / Offer period	One working day prior to the Bid / Offer opening date i.e. July 26, 2021
Bid/Offer Opening Date	July 27, 2021
Bid/ Offer Closing Date	July 29, 2021
Expected Date of Listing	August 6, 2021

This is for your kind information and record.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Limited



Harish Kuber

Company Secretary and Compliance Officer

Tel: 4018 9999 / 4018 9879

Fax: 4018 9986 (Legal & Secretarial Dept.)

